Cargando…

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells

Two major barriers to cancer immunotherapy include tumor-induced immune suppression mediated by myeloid-derived suppressor cells and poor immunogenicity of the tumor-expressing self-antigens. To overcome these barriers, we reprogrammed tumor-immune cell cross-talk by combined use of decitabine and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Payne, Kyle K., Keim, Rebecca C., Graham, Laura, Idowu, Michael O., Wan, Wen, Wang, Xiang-Yang, Toor, Amir A., Bear, Harry D., Manjili, Masoud H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Leukocyte Biology 2016
Materias:	Translational & Clinical Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982610/ https://www.ncbi.nlm.nih.gov/pubmed/26928306 http://dx.doi.org/10.1189/jlb.5A1215-580R

Ejemplares similares

Gr1(−/low)CD11b(−/low)MHCII(+) myeloid cells boost T cell anti‐tumor efficacy
por: Payne, Kyle K., et al.
Publicado: (2018)

Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk
por: Payne, Kyle K., et al.
Publicado: (2012)

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure
por: Kmieciak, Maciej, et al.
Publicado: (2011)

Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance
por: Katopodi, Theodora, et al.
Publicado: (2022)

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy
por: Aqbi, Hussein F., et al.
Publicado: (2018)

Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells
por: Payne, Kyle K, et al.
Publicado: (2013)

IFN-γ Rα Is a Key Determinant of CD8+ T Cell-Mediated Tumor Elimination or Tumor Escape and Relapse in FVB Mouse
por: Kmieciak, Maciej, et al.
Publicado: (2013)

The Janus Face of Death Receptor Signaling during Tumor Immunoediting
por: O’ Reilly, Eimear, et al.
Publicado: (2016)

Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics
por: Najaflou, Meysam, et al.
Publicado: (2022)

Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth
por: Enderling, Heiko, et al.
Publicado: (2012)

Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
por: Efremova, Mirjana, et al.
Publicado: (2018)

Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy
por: Sonabend, Adam M., et al.
Publicado: (2021)

Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets
por: Aqbi, Hussein F., et al.
Publicado: (2020)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors
por: Zhang, Xiaonan, et al.
Publicado: (2015)

Modeling cancer immunoediting in tumor microenvironment with system characterization through the ising-model Hamiltonian
por: Rojas-Domínguez, Alfonso, et al.
Publicado: (2022)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

Radiosensitivity of quiescent and proliferating cells grown as multicellular tumor spheroids
por: Onozato, Yusuke, et al.
Publicado: (2017)

The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution
por: Ballhausen, Alexej, et al.
Publicado: (2020)

Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2022)

Successful Extirpation of an Intra-Cranial Tumor
por: Campbell, F. R.
Publicado: (1886)

Cancer stem cell immunoediting by IFNγ
por: Galassi, Claudia, et al.
Publicado: (2023)

Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems
por: Manjili, Masoud H., et al.
Publicado: (2012)

OR09-1 Decoding Cancer Immunoediting of Tumor Microenvironment Provides Immunogenomic Marker for Thyroid Cancer Screening
por: Ali, Sophia, et al.
Publicado: (2022)

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
por: Adachi, Yusuke, et al.
Publicado: (2022)

Exosomes in cancer immunoediting and immunotherapy
por: Zhao, Yarong, et al.
Publicado: (2022)

Cancer Immunoediting and beyond in 2021
por: Borroni, Elena Monica, et al.
Publicado: (2021)

The adaptation model of immunity: Is the goal of central tolerance to eliminate defective T cells or self‐reactive T cells?
por: Manjili, Masoud H.
Publicado: (2022)

From Reductionistic Approach to Systems Immunology Approach for the Understanding of Tumor Microenvironment
por: Koelsch, Nicholas, et al.
Publicado: (2023)

Inhibition of Cdk5 induces cell death of tumor-initiating cells
por: Mandl, Melanie M, et al.
Publicado: (2017)

Have Cells Harboring the HIV Reservoir Been Immunoedited?
por: Huang, Szu-Han, et al.
Publicado: (2019)

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005)

A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
por: Loktev, Anastasia, et al.
Publicado: (2018)

329 Longitudinal immune profiling reveals unique myeloid and T cell phenotypes associated with spontaneous immunoediting in a novel prostate tumor model
por: Ager, Casey, et al.
Publicado: (2022)

Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer
por: Jahanban-Esfahlan, Rana, et al.
Publicado: (2019)

Frequent PD-L1 expression in testicular germ cell tumors
por: Fankhauser, C D, et al.
Publicado: (2015)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
por: Taylor-Harding, B, et al.
Publicado: (2012)

Quiescent Cancer Cells—A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse
por: Lindell, Emma, et al.
Publicado: (2023)

Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells
por: Lu, Xi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0gebv15shisj63g67ia6p3i3ql